Comparison of Efficacy and Safety of Combined Chemoimmunotherapy With or Without Radiation Therapy for Stage IVB Esophageal Squamous Cell Carcinoma: A Multicenter Propensity Score Matching Analysis

被引：3

作者：

Chen, Biqi ^{[1
,2
]}

Chen, Wenyan ^{[1
,2
,10
]}

Cheng, Qi ^{[3
]}

Zhang, Hao ^{[4
]}

Wang, Bingyi ^{[5
]}

Xu, Yujin ^{[3
]}

Yang, Chen ^{[1
,2
]}

Cheng, Xingyuan ^{[1
,2
]}

Wang, Ruixi ^{[1
,2
]}

Wang, Sifen ^{[1
,2
]}

Cen, Peiying ^{[1
,2
]}

Wang, Lin ^{[3
]}

Dragomir, Mihnea P. ^{[6
,7
,8
,9
]}

Zhu, Yujia ^{[1
,2
]}

Liu, Shiliang ^{[1
,2
]}

Xi, Mian ^{[1
,2
]}

Li, Qiaoqiao ^{[1
,2
]}

Chen, Baoqing ^{[1
,2
]}

机构：

[1] Sun Yat Sen Univ, Guangdong Prov Clin Res Ctr Canc, State Key Lab Oncol South China, Dept Radiat Oncol,Canc Ctr, Guangzhou, Peoples R China

[2] Guangdong Esophageal Canc Res Inst, Guangzhou, Peoples R China

[3] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med HIM, Dept Thorac Radiotherapy, Hangzhou, Zhejiang, Peoples R China

[4] Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Dept Radiat Oncol, Wuhan, Peoples R China

[5] Fujian Med Univ, Fujian Canc Hosp, Dept Radiat Oncol, Clin Oncol Sch, Fuzhou, Peoples R China

[6] Charite Univ Med Berlin, Inst Pathol, Berlin, Germany

[7] Humboldt Univ, Freie Univ Berlin, Berlin, Germany

[8] Berlin Inst Hlth, Berlin, Germany

[9] German Canc Consortium DKTK, German Canc Res Ctr DKFZ, Partner Site Berlin, Heidelberg, Germany

[10] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Oncol, Hengyang, Peoples R China

来源：

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 04期

关键词：

METASTATIC ESOPHAGEAL; PLUS CHEMOTHERAPY; CANCER; RADIOTHERAPY; SURVIVAL; CHEMORADIOTHERAPY; CONCURRENT; OUTCOMES; PLACEBO;

D O I：

10.1016/j.ijrobp.2024.06.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: This study aimed to compare the efficacy fi cacy and safety of combining fi rst-line chemoimmunotherapy with radiation therapy versus chemoimmunotherapy alone in patients with stage IVB esophageal squamous cell carcinoma (ESCC). Methods and Materials: We retrospectively examined 409 patients with stage IVB ESCC who received fi rst-line chemotherapy and anti-PD-1 antibody, with or without radiation therapy of >= 40 Gy radiation dose to primary lesion, from 4 academic cancer centers between October 2018 and December 2022. Propensity score matching was conducted to minimize the potential confounding effects. Results: In the overall cohort of 409 patients, the group that received additional radiation therapy had superior overall survival (OS) (hazard ratio [HR], 0.51; 95% CI, 0.39-0.66; P < .001) and progression-free survival (PFS) (HR, 0.52; 95% CI, 0.40-0.66; P < .001) compared to the group that received chemoimmunotherapy alone. After 1:1 propensity score matching, matching age, tumor location, and metastatic sites, a total of 250 patients were selected for further analysis. The results remained consistent and showed that the addition of radiation therapy significantly fi cantly improved OS and PFS (median OS, 24.9 vs 14.6 months; P = .003; median PFS, 14.2 vs 10.6 months; P = .002). Multivariate Cox analysis including tumor location, T stage, metastatic sites, and treatment modality, revealed that radiation therapy was an independent prognostic factor for both OS (HR, 0.57; 95% CI, 0.41-0.81) and PFS (HR, 0.63, 95% CI, 0.47-0.86). Subgroup analyses revealed significant fi cant OS prolongation in patients with nonregional lymph node metastases only who received radiation therapy (HR, 0.49; 95% CI, 0.34-0.70). No OS survival benefit fi t was observed in those with distant organ metastases (HR, 0.72; 95% CI, 0.46-1.13). Regarding safety, the group receiving additional radiation therapy had higher incidences of grade 3 to 4 lymphopenia (74.4% vs 17.7%, P < .001) and esophagitis (11.2% vs 2.4%, P = .006). Conclusions: The addition of radiation therapy to chemoimmunotherapy improved the survival of stage IVB ESCC patients with nonregional lymph node metastasis. (c) 2024 Published by Elsevier Inc.

引用

页码：1084 / 1095

页数：12

共 42 条

[21] Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial [J].

Lu, Zhihao ;

Wang, Junye ;

Shu, Yongqian ;

Liu, Lianke ;

Kong, Li ;

Yang, Lei ;

Wang, Buhai ;

Sun, Guogui ;

Ji, Yinghua ;

Cao, Guochun ;

Liu, Hu ;

Cui, Tongjian ;

Li, Na ;

Qiu, Wensheng ;

Li, Gaofeng ;

Hou, Xinfang ;

Luo, Hui ;

Xue, Liying ;

Zhang, Yanqiao ;

Yue, Wenbin ;

Liu, Zheng ;

Wang, Xiuwen ;

Gao, Shegan ;

Pan, Yueyin ;

Galais, Marie-Pierre ;

Zaanan, Aziz ;

Ma, Zhuo ;

Li, Haoyu ;

Wang, Yan ;

Shen, Lin .

BMJ-BRITISH MEDICAL JOURNAL, 2022, 377

[22] Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial [J].

Luo, Huiyan ;

Lu, Jin ;

Bai, Yuxian ;

Mao, Teng ;

Wang, Jun ;

Fan, Qingxia ;

Zhang, Yiping ;

Zhao, Kuaile ;

Chen, Zhendong ;

Gao, Shegan ;

Li, Jiancheng ;

Fu, Zhichao ;

Gu, Kangsheng ;

Liu, Zhihua ;

Wu, Lin ;

Zhang, Xiaodong ;

Feng, Jifeng ;

Niu, Zuoxing ;

Ba, Yi ;

Zhang, Helong ;

Liu, Ying ;

Zhang, Li ;

Min, Xuhong ;

Huang, Jing ;

Cheng, Ying ;

Wang, Dong ;

Shen, Yu ;

Yang, Qing ;

Zou, Jianjun ;

Xu, Rui-Hua .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (10) :916-925

[23] Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study [J].

Lyu, Jiahua ;

Li, Tao ;

Wang, Qifeng ;

Li, Fang ;

Diao, Peng ;

Liu, Li ;

Li, Churong ;

Lang, Jinyi .

RADIATION ONCOLOGY, 2018, 13

[24] Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment [J].

Sato, Hiro ;

Okonogi, Noriyuki ;

Nakano, Takashi .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (05) :801-809

[25] The Role of Definitive Radiation and Surgery in Metastatic Esophageal Cancer: An NCDB Investigation [J].

Seyedin, Steven N. ;

Parekh, Kalpaj R. ;

Ginader, Timothy ;

Caster, Joseph M. .

ANNALS OF THORACIC SURGERY, 2021, 112 (02) :459-466

[26]

Siegel RL, 2023, CA-CANCER J CLIN, V73, P17, DOI [10.3322/caac.21763, 10.3322/caac.21820]

[27] First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial [J].

Song, Yan ;

Zhang, Bo ;

Xin, Dao ;

Kou, Xiaoge ;

Tan, Zhenbo ;

Zhang, Shu ;

Sun, Meili ;

Zhou, Jin ;

Fan, Min ;

Zhang, Ming ;

Song, Yongxiang ;

Li, Suyi ;

Yuan, Yuan ;

Zhuang, Wu ;

Zhang, Jingdong ;

Zhang, Li ;

Jiang, Hao ;

Gu, Kangsheng ;

Ye, Huangyang ;

Ke, Ying ;

Li, Jing ;

Wang, Qingyu ;

Zhu, Jun ;

Huang, Jing .

NATURE MEDICINE, 2023, 29 (02) :473-482

[28] Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study [J].

Sun, Jong-Mu ;

Shen, Lin ;

Shah, Manish A. ;

Enzinger, Peter ;

Adenis, Antoine ;

Doi, Toshihiko ;

Kojima, Takashi ;

Metges, Jean-Philippe ;

Li, Zhigang ;

Kim, Sung-Bae ;

Cho, Byoung Chul ;

Mansoor, Wasat ;

Li, Shau-Hsuan ;

Sunpaweravong, Patrapim ;

Maqueda, Maria Alsina ;

Goekkurt, Eray ;

Hara, Hiroki ;

Antunes, Luis ;

Fountzilas, Christos ;

Tsuji, Akihito ;

Oliden, Victor Castro ;

Liu, Qi ;

Shah, Sukrut ;

Bhagia, Pooja ;

Kato, Ken .

LANCET, 2021, 398 (10302) :759-771

[29] Factors Predictive of Improved Outcomes With Multimodality Local Therapy After Palliative Chemotherapy for Stage IV Esophageal Cancer [J].

Wang, Jingya ;

Suri, Jaipreet S. ;

Allen, Pamela K. ;

Liao, Zhongxing ;

Komaki, Ritsuko ;

Ho, Linus ;

Hofstetter, Wayne L. ;

Lin, Steven H. .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (03) :228-235

[30] Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial [J].

Wang, Zi-Xian ;

Cui, Chengxu ;

Yao, Jun ;

Zhang, Yanqiao ;

Li, Mengxia ;

Feng, Jifeng ;

Yang, Shujun ;

Fan, Yun ;

Shi, Jianhua ;

Zhang, Xizhi ;

Shen, Lin ;

Shu, Yongqian ;

Wang, Cailian ;

Dai, Tianyang ;

Mao, Teng ;

Chen, Long ;

Guo, Zengqing ;

Liu, Bo ;

Pan, Hongming ;

Cang, Shundong ;

Jiang, Yi ;

Wang, Junye ;

Ye, Min ;

Chen, Zhendong ;

Jiang, Da ;

Lin, Qin ;

Ren, Wei ;

Wang, Junsheng ;

Wu, Lin ;

Xu, Yong ;

Miao, Zhanhui ;

Sun, Meili ;

Xie, Conghua ;

Liu, Ying ;

Wang, Qifeng ;

Zhao, Lina ;

Li, Qi ;

Huang, Canhong ;

Jiang, Ke ;

Yang, Kunyu ;

Li, Daojun ;

Liu, Yunpeng ;

Zhu, Zhitu ;

Chen, Rixin ;

Jia, Liqun ;

Li, Wei ;

Liao, Wangjun ;

Liu, Hong-Xu ;

Ma, Daiyuan ;

Ma, Jie .

CANCER CELL, 2022, 40 (03) :277-+

← 1 2 3 4 5 →